Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380137 | 0.83 | PNP (0.50) | PNPGDAGAAKMT2ATK1 | |
| SCHEMBL7217325 | 0.81 | PNP (0.49) | PNPGDAGAAKMT2ATK1 | |
| SCHEMBL5054173 | 0.80 | PNP (0.54) | PNPGDAGAAKMT2APDE1A | |
| SCHEMBL6233163 | 0.78 | PNP (0.58) | PNPGDAGAAKMT2ATK1 | |
| SCHEMBL9885862 | 0.77 | PNP (0.45) | PNPHPRT1KMT2APDE1APDE1B | |
| SCHEMBL27586845 | 0.76 | PNP (0.53) | PNPGDAHPRT1KMT2ATK1 | |
| SCHEMBL27573642 | 0.76 | PNP (0.50) | PNPGDAHPRT1KMT2ATK1 | |
| SCHEMBL9386892 | 0.76 | PNP (0.47) | PNPGDAHPRT1KMT2ATK1 | |
| SCHEMBL60160 | 0.76 | PNP (0.47) | PNPGDAKMT2APDE4AADORA2A | |
| SCHEMBL22326708 | 0.76 | PNP (0.47) | PNPGDAGAAKMT2ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | PNP 302/4885GDA 286/4885HPRT1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.